The subscription period in Prostatype Genomics AB's (“Prostatype Genomics” or the “Company”) rights issue of units of initially approximately SEK 27.3 million ended on 4 June 2025 (the "Rights Issue"). The Rights Issue was subscribed to a total of approximately 81.6 percent, including pre-subscription commitments, meaning that top-down underwriting commitments of a total of approximately 18.4 percent are activated to achieve full subscription. Bottom underwriting commitments will not be utilized. Prostatype Genomics will thus be provided proceeds of approximately SEK 27.3 million before deduction of transaction related costs and repayment of bridge loan.

Comment from Fredrik Rickman, CEO of Prostatype Genomics
"We are very pleased with the interest shown in our rights issue. The capital raised will allow us to continue executing on our plans and delivering long-term value to our shareholders. We extend our sincere thanks to both existing and new investors for their support", says Fredrik Rickman, CEO of Prostatype Genomics.

Subscription, allocation and payment
The Rights Issue was subscribed to approximately SEK 22.3 million including pre-subscription commitments of approximately SEK 3.4 million and including set-off of Gerald Andriole's accumulated net remuneration of approximately SEK 2.1 million in accordance with the Board of Directors' report from the Annual General Meeting on 15 May 2025, which corresponds to a subscription rate of approximately 81.6 percent. In addition, underwriting commitments of a total of approximately SEK 5 million have been activated, corresponding to approximately 18.4 percent of the Rights Issue. The activated underwriting commitments refer to the top underwriting commitments, where the upper top-down underwriting tranche is fully activated and the second top-down underwriting tranche at the level 85.5-74.5 percent is partially activated, with approximately SEK 1.1 million. The bottom underwriting has thus not been activated. The Rights Issue is thus fully subscribed (including activated top-down underwriting commitments), meaning that Prostatype Genomics is provided with approximately SEK 27.3 million before deduction of transaction related costs of approximately SEK 4.9 million (of which approximately SEK 1.9 million refer to underwriting fees, provided that all underwriters desire to receive cash compensation) and repayment of bridge loan.

A total of 4,264,783 units were subscribed for with the support of pre-emptive unit rights, including pre-subscription commitments. In total, 1,309,032 units were subscribed without the support of pre-emptive unit rights, including Gerald Andriole's set-off and including activated underwriting commitments. Through the Rights Issue, 27,340,852 new shares and 20,505,639 warrants of series TO5 will thus be issued. The subscribers who are allocated units without unit rights will receive settlement notes, which are planned to be sent out after a formal board decision on allocation. Allotted units without pre-emptive unit rights shall be paid in accordance with the instructions on the settlement note.

Number of shares and share capital
When the Rights Issue has been registered with the Swedish Companies Registration Office, the total number of shares will have increased by 27,340,852 shares, from 6,835,213 shares to 34,176,065 shares and the Company's share capital will, upon registration, have increased by SEK 2,734,085.20, from SEK 683,521.30 to SEK 3,417,606.50. In addition, a total of 20,505,639 warrants of series TO5 will be issued. The shareholders who have not participated in the Rights Issue will be subject to a dilution effect corresponding to approximately 80 percent of the votes and capital.

Warrants of series TO5
One (1) warrant of series TO5 entitles the holder to subscribe for one (1) new share. The exercise price for the warrants of series TO5 will be set within an interval between SEK 0.10 and SEK 1.50 and will be set with a 30 percent discount of the 20-day volume weighted average price prior to the second day before the exercise period. Warrants of series TO5 can be exercised to subscribe for new shares in Prostatype Genomics during the period from and including 3 September 2025 until and including 17 September 2025. The warrants of series TO5 are planned to be subject to trading on Nasdaq First North Growth Market. The last day of trading in the warrants is planned to be 15 September 2025. Upon full exercise of TO5 to the highest exercise price, the Company will receive an additional approximately SEK 30.8 million before transaction related costs, through the warrants of series TO5.

Full terms and conditions for the warrants of series TO5 are available on the Company’s website.

Trading in BTU
Trading in BTU's will take place on Nasdaq First North Growth Market until after the Rights Issue has been registered with the Swedish Companies Registration Office. The registration is expected to take place around 18 June 2025.

Information to investors under the Screening of Foreign Direct Investment Act (2023:560)
As the Company conducts activities worthy of protection in accordance with the Screening of Foreign Direct Investment Act (2023:560), certain investments in the Rights Issue may require examination by the Inspectorate for Strategic Products. For more information, please visit the Swedish Inspectorate for Strategic Products' website, www.isp.se or contact the Company.

Advisors
Navia Corporate Finance AB and Gemstone Capital ApS are financial advisors and Bookrunners in connection with the Rights Issue. Advokatfirman Lindahl is the legal advisor. Nordic Issuing AB is the issuing agent.

For more information about the Rights Issue, please contact:
Navia Corporate Finance AB
E-mail: info@naviacf.se
Website: www.naviacorporatefinance.com

or

Gemstone Capital ApS
E-mail: info@gemstonecapital.com
Website: www.gemstonecapital.com

For more information about the Company, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
E-mail: fredrik.rickman@prostatypegenomics.com

Certified Adviser
DNB Carnegie Investment Bank AB
Telephone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se

About Prostatype Genomics
Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB. The Company’s Certified Adviser is DNB Carnegie.

Important information
The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Prostatype Genomics. No action has been taken, and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden. The invitation to interested persons to subscribe for shares in Prostatype Genomics takes place solely through the prospectus that Prostatype Genomics has published.

The information contained in this press release may not be disclosed, published or distributed, directly or indirectly, within or to the United States, Belarus, Russia, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. No shares or other securities of Prostatype Genomics have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933 from time to time ("Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and pursuant to the securities laws of the relevant state or other jurisdiction in the United States. This communication is distributed to and directed solely to persons in the United Kingdom who are (i) professional investors falling within the scope of Article 19(5) of the U.K. from time to time in force; Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("the Order") or (ii) high net worth subjects and other persons to whom this notice may lawfully be addressed, who are subject to Article 49(2)(a)-(d) ) in the Order (all such persons are collectively referred to as "Relevant Persons"). Persons who are not Relevant Persons may not act on or rely on the information in this communication. An investment or investment measure referred to in this communication is only possible for Relevant Persons and will only be completed with Relevant Persons. Persons who disseminate this communication must themselves ensure that such dissemination is permitted.

Forward-looking Statements
This press release contains forward-looking statements that refer to the Company's intentions, assessments or expectations regarding the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies and opportunities as well as the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the inclusion of expressions such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "assumes", “should" "could" and, in each case, negations thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will occur or that they are accurate. As these
assumptions are based on assumptions or estimates and are subject to risks and uncertainties, the actual result or outcome may, for many different reasons, differ materially from what appears in the forward-looking statements.

Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in this press release through the forward-looking statements. The Company does not warrant that the assumptions underlying the forward-looking statements in this press release are correct and any reader of the press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements expressed or implied herein are provided only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to revise, update, confirm or publicly announce any revision of any forward-looking statement to reflect events occurring or circumstances occurring with respect to the contents of this press release, except as required by law or Nasdaq First North Growth Markets' regulations for issuers.